Cellares and Papillon Therapeutics Partner to Automate Manufacturing of PPL-001 Gene-Edited Cell Therapy for Friedreich’s Ataxia
Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO) dedicated to advancing cell therapy manufacturing, has announced a strategic collaboration with Papillon Therapeutics Inc., a clinical-stage biotechnology company developing multi-systemic genetic medicines for inherited diseases. The partnership will focus on automating the manufacturing process for PPL-001, Papillon’s investigational gene-corrected hematopoietic stem and progenitor cell (HSPC) therapy designed to address the underlying genetic cause of Friedreich’s ataxia (FA).
The collaboration combines Papillon’s expertise in gene-editing therapeutics with Cellares’ advanced automated manufacturing technologies. Under the agreement, Cellares will adapt the manufacturing process for PPL-001 to its proprietary Cell Shuttle® platform while supporting product quality and release testing through its automated Cell Q™ quality control system.
By replacing labor-intensive manual manufacturing with an integrated, closed-system automated workflow, the companies aim to improve manufacturing consistency, enhance scalability, reduce production variability, and prepare the therapy for both future clinical development and potential commercial manufacturing.
The partnership reflects a growing industry trend toward automation in advanced cell and gene therapies, where manufacturing precision plays a critical role in ensuring product quality, patient safety, and commercial viability.
Advancing a Gene-Edited Therapy for Friedreich’s Ataxia
PPL-001 is Papillon Therapeutics’ lead investigational therapy and is being developed as a gene-corrected hematopoietic stem and progenitor cell treatment for patients with Friedreich’s ataxia.
Unlike conventional therapies that primarily manage symptoms, PPL-001 is designed to address the genetic mutation responsible for the disease itself.
The therapy utilizes targeted gene editing to correct the GAA repeat expansion located within Intron 1 of the FXN gene, the mutation responsible for more than 95% of Friedreich’s ataxia cases.
By correcting the defective gene in a patient’s own hematopoietic stem and progenitor cells, researchers hope to restore normal frataxin production and potentially alter the course of disease progression.
This precision-based strategy represents a significant advancement in the field of genetic medicine, where therapies increasingly focus on correcting the underlying causes of inherited disorders rather than treating downstream symptoms.
Understanding Friedreich’s Ataxia
Friedreich’s ataxia is a rare, inherited neurodegenerative disorder that affects multiple organ systems throughout the body.
The disease typically develops during childhood or adolescence, although age of onset can vary among individuals.
Because the condition affects numerous tissues simultaneously, patients often experience progressive neurological decline alongside significant cardiac and metabolic complications.
Common manifestations include:
- Progressive loss of coordination
- Difficulty walking
- Balance impairment
- Muscle weakness
- Speech difficulties
- Hypertrophic cardiomyopathy
- Skeletal muscle dysfunction
- Pancreatic involvement
Over time, many patients lose mobility and require assistive devices while facing increased risks associated with cardiac complications.
Despite ongoing advances in supportive care, there remains no approved curative treatment capable of correcting the underlying genetic defect responsible for Friedreich’s ataxia.
This substantial unmet medical need has driven continued investment in innovative gene-editing approaches such as PPL-001.
Correcting the Root Cause of Disease
The FXN gene encodes frataxin, a protein that plays an essential role in mitochondrial function and cellular energy production.
In Friedreich’s ataxia, abnormal expansion of GAA DNA repeats significantly reduces frataxin production, leading to progressive cellular dysfunction across multiple organ systems.
Rather than replacing the defective gene through traditional gene addition strategies, PPL-001 employs targeted gene editing designed to directly correct the disease-causing mutation.
Because more than 95% of Friedreich’s ataxia patients carry the same GAA repeat expansion, this strategy has the potential to benefit a large proportion of individuals affected by the disease.
If successful, gene correction may provide durable therapeutic benefit by restoring normal gene function within a patient’s own stem cells.
Regulatory Recognition Highlights Clinical Potential
PPL-001 has already received important regulatory designations from the U.S. Food and Drug Administration (FDA), reflecting both the rarity of the disease and the significant unmet medical need it represents.
The therapy has been granted:
- Orphan Drug Designation
- Rare Pediatric Disease Designation
These regulatory programs are intended to encourage development of therapies for serious rare diseases by providing incentives such as regulatory support, market exclusivity, and other development benefits.
In addition to regulatory recognition, development of PPL-001 has received financial support from several respected organizations dedicated to advancing research in rare diseases.
Funding has been provided in part by:
- California Institute for Regenerative Medicine (CIRM)
- Friedreich’s Ataxia Research Alliance (FARA)
- National Institutes of Health (NIH)
This broad institutional support underscores the scientific promise of the program and the importance of developing transformative treatments for patients with Friedreich’s ataxia.
Automating Manufacturing with the Cell Shuttle®
Under the collaboration, Cellares will transfer the manufacturing process for PPL-001 onto its proprietary Cell Shuttle® platform.
The Cell Shuttle is an automated, end-to-end manufacturing system specifically designed for advanced cell therapies.
Traditional cell therapy manufacturing often relies on multiple manual processing steps that require highly trained personnel and can introduce variability between manufacturing batches.
By contrast, the Cell Shuttle performs manufacturing within a closed automated environment.
Its integrated workflow is intended to provide:
- Greater manufacturing consistency
- Reduced operator variability
- Improved reproducibility
- Enhanced scalability
- Lower manufacturing costs
Automation is particularly valuable for gene-edited hematopoietic stem cell therapies because these products require highly controlled handling throughout every stage of production.
Maintaining precise processing conditions helps ensure consistent gene editing, cell viability, and overall product quality.
Supporting Quality Through Cell Q™
In addition to manufacturing support, Cellares will provide automated quality control and release testing using its Cell Q™ platform.
Quality testing represents one of the most important components of advanced cell therapy manufacturing.
Each manufactured batch must undergo extensive analytical testing before being released for clinical use.
Cell Q™ has been designed to automate many of these analytical processes, helping streamline quality assessment while reducing manual laboratory work.
Automated release testing may improve manufacturing efficiency while supporting regulatory compliance and product consistency.
Together, the Cell Shuttle and Cell Q platforms create an integrated manufacturing ecosystem capable of supporting advanced cell therapy development from production through quality release.
Addressing Manufacturing Challenges in Cell Therapy
Manufacturing remains one of the greatest challenges facing the cell and gene therapy industry.
Unlike conventional pharmaceutical products, autologous cell therapies require individualized manufacturing using cells collected from each patient.
This process involves multiple complex steps, including:
- Cell collection
- Gene editing
- Cell expansion
- Quality testing
- Product release
Each step must be carefully controlled to ensure safety and therapeutic effectiveness.
Automation has emerged as one of the industry’s most promising solutions for overcoming manufacturing bottlenecks while improving scalability.
Cellares has positioned itself as a leader in this field by developing manufacturing technologies capable of supporting both small rare disease programs and larger commercial indications.
Supporting Rare Disease Development
Although much attention within cell therapy has focused on diseases affecting large patient populations, developers of rare disease therapies often face equally significant manufacturing challenges.
Small patient populations do not reduce the complexity of manufacturing.
Instead, companies must often balance limited production volumes with the need for exceptionally high manufacturing precision.
Cellares believes its flexible manufacturing infrastructure allows developers like Papillon to efficiently support both:
- Early-stage clinical trials
- Future global commercial manufacturing
The platform is designed to accommodate programs ranging from ultra-rare pediatric diseases to large autoimmune indications requiring hundreds of thousands of annual doses.
Company Leaders Highlight the Partnership
Carter Cliff, Chief Executive Officer of Papillon Therapeutics, described the collaboration as an important milestone in advancing PPL-001 toward clinical development.
He noted that Friedreich’s ataxia is a devastating inherited disease that frequently begins during childhood or adolescence and emphasized that PPL-001 seeks to address its underlying genetic cause.
According to Cliff, achieving consistent gene correction across patient-derived CD34+ stem cell populations requires a level of manufacturing precision that traditional manual processes cannot reliably provide.
He stated that Cellares’ automated manufacturing platform offers the process control needed to support both clinical development and eventual commercial launch.
Fabian Gerlinghaus, Co-founder and Chief Executive Officer of Cellares, emphasized that manufacturing challenges extend beyond therapies targeting large patient populations.
He explained that developers working on rare diseases often face equally complex manufacturing requirements.
Gerlinghaus described PPL-001 as a scientifically compelling program addressing a disease without an approved curative treatment and noted that Cellares’ Cell Shuttle and Cell Q platforms were specifically designed to deliver the precision, consistency, and scalability required for advanced gene-corrected HSPC therapies.
The collaboration between Cellares and Papillon Therapeutics represents an important advancement in the development of next-generation gene-edited therapies for rare inherited diseases. By integrating Papillon’s innovative PPL-001 program with Cellares’ automated Cell Shuttle® manufacturing platform and Cell Q™ quality control system, the companies aim to overcome one of the most significant challenges in cell therapy development—consistent, scalable, and high-quality manufacturing.
As PPL-001 progresses toward clinical evaluation, the partnership provides a strong manufacturing foundation capable of supporting both early-stage clinical studies and future commercial production. More broadly, the collaboration highlights the growing importance of automation in cell and gene therapy manufacturing, particularly for complex personalized treatments targeting rare diseases. If successful, this integrated approach could accelerate the delivery of potentially transformative therapies for patients living with Friedreich’s ataxia, a devastating inherited disorder for which curative treatment options remain unavailable.
About Papillon Therapeutics
Papillon is dedicated to delivering cures from within by harnessing the body’s own cells. Overcoming the targeting barriers of traditional genetic medicines, the company’s proprietary platform utilizes patient-derived hematopoietic stem cells to systemically distribute functional proteins across multiple affected organs.
Papillon’s lead program, PPL-001, is a one-time, potentially lifetime-durable treatment designed to arrest the progression of Friedreich’s ataxia across affected tissues—including the brain, spine, heart, and pancreas. Validated by a landmark clinical partnership with Novartis, Papillon is advancing a pipeline of transformative cell therapies engineered to restore health across a lifetime. For more information, visit https://papillon-tx.com/ and follow Papillon on LinkedIn.
About Cellares
Cellares is the first Integrated Development and Manufacturing Organization (IDMO), providing global cell therapy development and manufacturing services through an Industry 4.0 approach to the mass manufacture of the living drugs of the 21st century. The company enables drug sponsors to develop, scale, and commercialize cell therapies with the capacity, reliability, and economics required to meet total patient demand.
Cellares’ fully automated platforms — Cell Shuttle® for end-to-end cell therapy manufacturing and Cell Q™ for automated in-process and release quality control — are deployed across its network of IDMO Smart Factories worldwide. These technologies deliver industry-leading manufacturing economics, higher process success rates, and the ability to produce up to 10× more cell therapy batches than conventional CDMOs with comparable footprint and headcount, resulting in the lowest cost of manufacturing in the industry.
The Cell Shuttle is the first cell therapy manufacturing platform to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, and has demonstrated a 100% automation success rate across more than a dozen automated processes.
Cellares has achieved key clinical validation milestones, including a successful IND Amendment enabling active clinical manufacturing on the Cell Shuttle platform, and the successful dosing of first patients in a partner clinical trial — marking the platform’s transition from development-stage technology to clinically validated manufacturing infrastructure. These milestones span multiple therapeutic areas and cell therapy modalities, including both oncology and autoimmune indications.
Headquartered in South San Francisco, California, Cellares operates its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey, with additional facilities under construction in Europe and Japan. Through its global manufacturing network, Cellares is purpose-built to support both clinical and commercial programs and to expand access to life-saving cell therapies worldwide.